배양된 인간 골막기원세포의 조골활성에 대한 덱사메타손 농도의 효과 (EFFECT OF DEXAMETHASONE CONCENTRATIONS ON OSTEOGENIC ACTIVITY OF CULTURED HUMAN PERIOSTEAL-DERIVED CELLS)

서지정보

· 발행기관 : 대한악안면성형재건외과학회
· 수록지 정보 : Maxillofacial Plastic Reconstructive Surgery / 31권 / 4호 / 287 ~ 293페이지
· 저자명 : 김종렬, 박봉욱, 하영술, 김덕룡, 조영철, 성일용, 변준호, 이창일

초록

Long-term treatment with glucocorticoid leads to the development of osteoporosis and osteonecrosis. In
contrast to the marked inhibitory effect of pharmacological doses of glucocorticoids on bone formation, the
relationship between physiological concentrations of glucocorticoids and osteoprogenitor cell proliferation
and phenotypes has not been elucidated yet. In addition, the effects of dexamethasone treatment on the
proliferation and osteoblastic differentiation of osteoprogenitor cells are also controversial. The purpose of
this study was to examine the effects of dexamethasone on the proliferation and osteoblastic differentiation
of periosteal-derived cells. Periosteal-derived cells were obtained from mandibular periosteums and introduced
into the cell culture. After passage 3, the cells were further cultured for 21 days in the osteogenic
induction medium with different dexamethasone concentrations of 0, 10, and 100 nM. The proliferation
and osteoblastic phenotypes of periosteal-derived cells were promoted in dexamethasone-treated cells than
in untreated cells. Among the dexamethasone-treated cells, cell proliferation was slightly greater in 10 nM
dexamethasone-treated cells than in 100 nM dexamethasone-treated cells. Histochemical staining and the
bioactivity of alkaline phosphatase (ALP) were higher in 100 nM dexamethasone-treated cells than in 10
nM dexamethasone-treated cells. Similarly, von Kossa-positive mineralization nodules and calcium content
were also more evident in 100 nM dexamethasone-treated cells than in 10 nM dexamethasone-treated
cells. These results suggest that dexamethasone enhances the in vitro osteoblastic differentiation of
periosteal-derived cells. The present study also demonstrates that higher dexamethasone concentrations
reduce the in vitro proliferation of periosteal-derived cells.

영어초록

Long-term treatment with glucocorticoid leads to the development of osteoporosis and osteonecrosis. In
contrast to the marked inhibitory effect of pharmacological doses of glucocorticoids on bone formation, the
relationship between physiological concentrations of glucocorticoids and osteoprogenitor cell proliferation
and phenotypes has not been elucidated yet. In addition, the effects of dexamethasone treatment on the
proliferation and osteoblastic differentiation of osteoprogenitor cells are also controversial. The purpose of
this study was to examine the effects of dexamethasone on the proliferation and osteoblastic differentiation
of periosteal-derived cells. Periosteal-derived cells were obtained from mandibular periosteums and introduced
into the cell culture. After passage 3, the cells were further cultured for 21 days in the osteogenic
induction medium with different dexamethasone concentrations of 0, 10, and 100 nM. The proliferation
and osteoblastic phenotypes of periosteal-derived cells were promoted in dexamethasone-treated cells than
in untreated cells. Among the dexamethasone-treated cells, cell proliferation was slightly greater in 10 nM
dexamethasone-treated cells than in 100 nM dexamethasone-treated cells. Histochemical staining and the
bioactivity of alkaline phosphatase (ALP) were higher in 100 nM dexamethasone-treated cells than in 10
nM dexamethasone-treated cells. Similarly, von Kossa-positive mineralization nodules and calcium content
were also more evident in 100 nM dexamethasone-treated cells than in 10 nM dexamethasone-treated
cells. These results suggest that dexamethasone enhances the in vitro osteoblastic differentiation of
periosteal-derived cells. The present study also demonstrates that higher dexamethasone concentrations
reduce the in vitro proliferation of periosteal-derived cells.

참고자료

· 없음